Not provided
Not provided
Not provided
Not provided
Not provided
COVID-19 prevented us from doing this human subjects study
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
People living with HIV are living longer as their disease is controlled with antiretroviral medications. Yet they are experiencing frailty more often and more than ten years earlier than those without HIV. In elderly persons without HIV, frailty is associated with decreased muscle strength and chronic inflammation. Less is known about what is driving early frailty in HIV or effective prevention measures for aging adults with HIV.
It may be that having HIV infection impairs energy production by mitochondria within the cells and contributes to the muscle weakness and inflammation accompanying frailty in people living with HIV . This study will examine the impact of six weeks of moderately paced walking on energy production in the cells, inflammation markers and frailty scores in people living with well-controlled HIV who are aged 50 to 65.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| People living with HIV | Other | Subjects will act as own control between Visit one and Visit two, then will complete six weeks of walking, 30 minutes per walk, three times weekly between Visit Two and Visit Three. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Walking | Behavioral | Moderately paced walking of approximately 100 steps/minute for 30 minutes three times weekly for six weeks. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Mitochondrial Respiration PBMC and platelets | Change in mitochondrial respiratory capacity after a six-week walking intervention | Day 0, Week 6, Week 12 with intervention between weeks 6 and 12 |
| Measure | Description | Time Frame |
|---|---|---|
| Inflammation IL-1β | Change in IL-1β after a six-week walking intervention | Day 0, Week 6, Week 12 with intervention between weeks 6 and 12 months |
| Inflammation IL-6 | Change in IL-6 after a six-week walking intervention |
| Measure | Description | Time Frame |
|---|---|---|
| Frailty Related Phenotype | Change in frailty phenotype score (0-5 with 3 to 5 indicating frailty) after a six-week walking intervention | Day 0, Week 6, Week 12 with intervention between weeks 6 and 12 |
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Jennifer Klinedinst, PhD | Associate Professor | Principal Investigator |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D000163 | Acquired Immunodeficiency Syndrome |
| D000073496 | Frailty |
| D009043 | Motor Activity |
| D007249 | Inflammation |
| ID | Term |
|---|---|
| D015658 | HIV Infections |
| D000086982 | Blood-Borne Infections |
| D003141 | Communicable Diseases |
| D007239 | Infections |
Not provided
Not provided
| ID | Term |
|---|---|
| D016138 | Walking |
| D015444 | Exercise |
| ID | Term |
|---|---|
| D008124 | Locomotion |
| D009068 | Movement |
| D009142 | Musculoskeletal Physiological Phenomena |
| D055687 | Musculoskeletal and Neural Physiological Phenomena |
Not provided
Not provided
This within-subjects design will allow each subject to be utilized as their own control pre-intervention. With expectation of great inter-person variability of oxygen consumption results, this design will incorporate less error than separately recruited controls and decrease the needed sample size.
Not provided
Not provided
Not provided
Not provided
| Day 0, Week 6, Week 12 with intervention between weeks 6 and 12 |
| Inflammation IL-10 | Change in IL-10 after a six-week walking intervention | Day 0, Week 6, Week 12 with intervention between weeks 6 and 12 |
| Inflammation TNF-α | Change in TNF-α after a six-week walking intervention | Day 0, Week 6, Week 12 with intervention between weeks 6 and 12 |
| Inflammation hsCRP | Change in hsCRP after a six-week walking intervention | Day 0, Week 6, Week 12 with intervention between weeks 6 and 12 |
| D015229 |
| Sexually Transmitted Diseases, Viral |
| D012749 | Sexually Transmitted Diseases |
| D016180 | Lentivirus Infections |
| D012192 | Retroviridae Infections |
| D012327 | RNA Virus Infections |
| D014777 | Virus Diseases |
| D012897 | Slow Virus Diseases |
| D000091662 | Genital Diseases |
| D000091642 | Urogenital Diseases |
| D007153 | Immunologic Deficiency Syndromes |
| D007154 | Immune System Diseases |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D001519 | Behavior |
| D009043 | Motor Activity |